Healthcare data firm IQVIA Q3 revenue beats on strong bookings

Overview

• Clinical research and healthcare data firm's Q3 revenue rose 8%, beating analyst expectations

• Adjusted diluted EPS for Q3 up 11%, beating analyst expectations

• Company raised full-year 2026 guidance for revenue, adjusted EBITDA and adjusted EPS

Outlook

• IQVIA raises full-year 2026 revenue guidance to $17.35 bln-$17.5 bln

• Company lifts 2026 adjusted EBITDA outlook to $4.025 bln-$4.055 bln

• IQVIA now expects 2026 adjusted diluted EPS of $12.90-$13.00

Result Drivers

• STRONG BOOKINGS - Co reported R&D Solutions net new bookings rose 15% year-over-year to $3.2 bln, resulting in its strongest clinical quarterly bookings since 2022

• AI SOLUTIONS DEPLOYMENT - Co said increased use of AI-powered solutions, with over 400 AI agents deployed, contributed to organic growth acceleration

• FAVORABLE MARKET ENVIRONMENT - Co cited strong demand indicators such as EBP funding, RFP flow, clinical trial starts, FDA approvals, outsourcing trends, and pipeline growth across clinical and commercial segments

Company press release: ID:nBw6NnZKha

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 20 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for IQVIA Holdings Inc is $300.00, about 9.6% above its October 26 closing price of $273.60

• The stock recently traded at 19 times the next 12-month earnings vs. a P/E of 14 three months ago

Reuters Recommended Reads

• Oct 26 - Canada's Celestica Q3 revenue jumps 83% on higher customer demand, operating leverage; raises 2026 outlook

• Oct 27 - Novartis slightly misses Q3 net sales estimates, but tops core EPS view

• Oct 26 - Cadence tops Q3 profit estimates, hikes forecast on AI-driven design strength

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)